Dr Carlos Barrios is president of the American Cooperative Oncology Group (LACOG) and director at the Oncology Research Center at Hospital São Lucas-PUCRS in Brazil. 

 

He graduated in medicine from the Pontifical University of Rio Grande do Sul (1979) and completed his Internal Medicine training at Hospital de Clínicas, URFGS, in Porto Alegre and Jackson Memorial Hospital, University of Miami from 1980 through 1985. He had his Hematology and Oncology training at the Washington University, Barnes and Jewish Hospitals in St Louis, US. 

 

He has been Director of the Oncology Research Center at Hospital São Lucas, PUCRS since 1996.  

 

He has a strong interest in the development of international research collaboration and implementation of cooperative research infrastructures in Latin America. As such, he is cofounder and current President of the LACOG (Latin American Cooperative Oncology Group) that congregates more than 600 investigators from 16 different countries in Latin America. 

 

His area of expertise and interest focus on Breast Cancer and Clinical Research – having participated in over 300 national and international Clinical Research projects over the last 2 decades.  He has more than 300 published manuscripts with more than 70.000 citations and has been included in the Clarivate list of the most cited researchers in the world since 2023.

Dr Carlos Barrios has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Grants/research support: (to the institution) Amgen, Astra Zeneca, Aveo Oncology, Beigene, Bicycle, BioNTech, Boehringer Ingelheim, BMS, Celcuity, CELLTRION, Daiichi Sankyo, Dizal Pharma, Fortrea, Genmab, Gilead Sciences, GSK, ICON, IQVIA, Intrials, Janssen, Jazz Pharmaceuticals, Labcorp, Lilly, mAbxience Research, Medpace, MEDSIR, Merus, Mirati Therapeutics,  MSD, Novartis, Novocure, Nuvisan, OBIPharma, Parexel,  Pfizer, PharmaMar, PPD, Regeneron, Roche/Genentech, Samsung, Sandoz, Seagen, Servier,  Shanghai Henlius, Stemline Therapeutics, Syneos Health, Taiho, Tolmar, TRIO, Worldwide.  

Academic Research Projects: CPO, PUCRS, LACOG, GBECAM.  

Ownership or Stocks: Tummi, MEDSir. 

CPO Advisory Boards, Consulting, Travel, Presentation Honoraria: Adium, Novartis, Pfizer, Roche/Genentech, MSD, Astra Zeneca, Lilly, Daiichi, Gilead.